BIOMARKER:

FGFR2 rearrangement

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval PRNewswire - 1 week (New A1) pemigatinib Sensitive : A1 PRNewswire - 1wk	pemigatinib Sensitive: A1 - Approval PRNewswire - 1 week pemigatinib Sensitive : A1 PRNewswire - 1 week - (New A1)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	TAS 120 Sensitive: B - Late Trials TAS 120 Sensitive : B	TAS 120 Sensitive: B - Late Trials TAS 120 Sensitive : B
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	FGFR inhibitor Sensitive: C3 – Early Trials FGFR inhibitor Sensitive : C3	FGFR inhibitor Sensitive: C3 – Early Trials FGFR inhibitor Sensitive : C3